PL3395350T3 - Lek medyczny do leczenia zawału mózgu - Google Patents

Lek medyczny do leczenia zawału mózgu

Info

Publication number
PL3395350T3
PL3395350T3 PL16879037.6T PL16879037T PL3395350T3 PL 3395350 T3 PL3395350 T3 PL 3395350T3 PL 16879037 T PL16879037 T PL 16879037T PL 3395350 T3 PL3395350 T3 PL 3395350T3
Authority
PL
Poland
Prior art keywords
treatment
medical drug
brain infarction
infarction
brain
Prior art date
Application number
PL16879037.6T
Other languages
English (en)
Inventor
Osamu Honmou
Masahito NAKAZAKI
Masanori Sasaki
Yuko Sasaki
Shinichi Oka
Original Assignee
Sapporo Medical University
Nipro Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapporo Medical University, Nipro Corporation filed Critical Sapporo Medical University
Publication of PL3395350T3 publication Critical patent/PL3395350T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
PL16879037.6T 2015-12-25 2016-12-26 Lek medyczny do leczenia zawału mózgu PL3395350T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015254410A JP6777840B2 (ja) 2015-12-25 2015-12-25 脳梗塞の治療用医薬
PCT/JP2016/088646 WO2017111153A1 (ja) 2015-12-25 2016-12-26 脳梗塞の治療用医薬

Publications (1)

Publication Number Publication Date
PL3395350T3 true PL3395350T3 (pl) 2022-08-16

Family

ID=59090568

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16879037.6T PL3395350T3 (pl) 2015-12-25 2016-12-26 Lek medyczny do leczenia zawału mózgu

Country Status (14)

Country Link
US (1) US20190002833A1 (pl)
EP (1) EP3395350B1 (pl)
JP (1) JP6777840B2 (pl)
KR (1) KR102859691B1 (pl)
CN (1) CN108367027B (pl)
AU (1) AU2016375880C1 (pl)
CA (1) CA3009313A1 (pl)
DK (1) DK3395350T3 (pl)
ES (1) ES2922247T3 (pl)
IL (1) IL260246B2 (pl)
PL (1) PL3395350T3 (pl)
PT (1) PT3395350T (pl)
SG (1) SG11201805358TA (pl)
WO (1) WO2017111153A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220125850A1 (en) * 2019-02-07 2022-04-28 Sapporo Medical University Pharmaceutical composition for preventing in-stent restenosis
US20220226386A1 (en) * 2019-05-23 2022-07-21 Mesoblast International Sárl Functional recovery from cerebral infarction
JP7849696B2 (ja) * 2020-11-26 2026-04-22 北海道公立大学法人 札幌医科大学 虚血性血管障害の治療用医薬

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295539A1 (en) 2000-06-26 2011-03-16 Nc Medical Research Inc. Cell fractions containing cells capable of differentiating into neural cells
US9682319B2 (en) 2002-07-31 2017-06-20 Sony Interactive Entertainment Inc. Combiner method for altering game gearing
CA2505251A1 (en) * 2002-11-05 2004-05-27 Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
KR101130220B1 (ko) * 2003-06-27 2012-04-13 엔씨 메디컬 리서치 가부시키가이샤 간엽계 세포를 유효 성분으로 하는 뇌신경 질환 치료용 체내 투여용 약제
US20060210544A1 (en) * 2003-06-27 2006-09-21 Renomedix Institute, Inc. Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
BR112013004700B1 (pt) * 2010-08-27 2020-12-08 Joshua M. Hare uso de células precursoras de células-tronco mesenquimais (msc) cd271+
JP5598864B2 (ja) * 2011-12-05 2014-10-01 北海道公立大学法人 札幌医科大学 細胞増殖方法ならびに組織の修復および再生のための医薬
JPWO2015046574A1 (ja) * 2013-09-30 2017-03-09 国立大学法人 新潟大学 虚血後の再灌流に起因する出血を予防するための薬剤
JPWO2015174087A1 (ja) * 2014-05-16 2017-04-20 公益財団法人先端医療振興財団 脳梗塞の予防及び／又は治療の為の医薬

Also Published As

Publication number Publication date
JP6777840B2 (ja) 2020-10-28
IL260246B2 (en) 2023-06-01
DK3395350T3 (da) 2022-07-11
IL260246A (en) 2018-07-31
EP3395350B1 (en) 2022-06-15
WO2017111153A1 (ja) 2017-06-29
KR20180096607A (ko) 2018-08-29
AU2016375880A1 (en) 2018-07-19
AU2016375880B2 (en) 2023-09-14
KR102859691B1 (ko) 2025-09-15
CN108367027A (zh) 2018-08-03
EP3395350A4 (en) 2019-09-18
AU2016375880C1 (en) 2024-01-04
EP3395350A1 (en) 2018-10-31
PT3395350T (pt) 2022-07-18
CN108367027B (zh) 2023-12-12
US20190002833A1 (en) 2019-01-03
SG11201805358TA (en) 2018-07-30
ES2922247T3 (es) 2022-09-12
CA3009313A1 (en) 2017-06-29
JP2017114827A (ja) 2017-06-29

Similar Documents

Publication Publication Date Title
ZA201800641B (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3191020T3 (da) Medicinsk/kirurgisk implantat
IL257355B (en) Selection of patients for combination therapy
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
HUE053443T2 (hu) Heteroaril vegyületek szembetegségek kezelésére
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
IL259297A (en) Heterocyclic compounds for the treatment of disease
IL262801A (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
ZA201805408B (en) Medicament for treatment of diabetic foot infections
IL259381B (en) Mirabegron for the treatment of retinal diseases
IL260246A (en) A drug for the treatment of myocardial infarction
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
PL3903774T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych
IL248253A0 (en) A medicine to treat tinnitus patients
IL248252A0 (en) A medicine to treat tinnitus patients
UA37478S (uk) Шприц медичний
GB201621398D0 (en) Treatment of emt-associated disease
UA28392S (uk) Кетгут для медичних потреб
PL3185855T3 (pl) Tabletka powlekana filmem do leczenia ostrego bólu
GB201504413D0 (en) Treatment of disease
UA31221S (uk) Турнікет кровоспинний на медичні потреби
GB201501800D0 (en) Treatment of medical conditions